Spatial biology
6078 Living in a Spatial World: Characterizing the Immune Environment in Tumors
shape Monitor
webinar
Angela Vasaturo, PhD; Lorcan Sherry, PhD

Associate Director Scientific Affairs, Ultivue; Chief Science Officer, OracleBio

Living in a Spatial World: Characterizing the Immune Environment in Tumors

77 minutes

Relevant for

InSituPlex

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors. Advances in technology in the past few years have created unprecedented opportunities to better identify biomarkers of disease processes, especially by using multi-omics technologies and datasets to derive valid and useful signatures of disease. Despite these advances, today only a minority of patients respond to immunotherapies. Prediction of response to therapies such as checkpoint inhibitors that rely on activation of endogenous immune responses has been shown to be especially difficult due to complex and heterogeneous immune escape mechanisms in each patient. Increasing evidence suggests that measurement of robust biomarkers through spatial analysis of the tissue will be key to enable rational patient selection for an improved clinical trial process and design precise combination therapies. To date, much of what has been learned about the tumor microenvironment (TME) has come from the use of IHC, but information has been limited by labor-intensive protocols that yield single data points. IHC method sare therefore not sufficient for generating the comprehensive and interactive picture of the TME landscape. Newer technological approaches, such as multiplex immunofluorescence (mIF), provide greater resolution, better use of precious samples, and unparalleled insight into the spatial cellular arrangement within the tumor. The quantitative assessment of the accuracy and precision of such multiplex panels however is key for their widespread use in clinical samples.

Webinar Learning Objectives

The development and validation process of a high throughput, high-plex mIF assay to derive meaningful biological insights.

Demonstrate how advanced AI-driven image analysis can be applied to discover cell types, populations and morphological context.

Discuss how whole slide image analysis of the tumor microenvironment can provide insight into specific cancer types.

Meet the hosts

Angela Vasaturo is the Associate Director Scientific Affairs at Ultivue. Prior to joining Ultivue she was a Senior Researcher in Dr. Jerome Galon’s Laboratory of Integrative Cancer Immunology at the Cordeliers Research Centre. She has a wealth of expertise in multiplex IHC techniques, multispectral digital pathology, and tissue imaging.

Author
Angela Vasaturo, PhD

Associate Director Scientific Affairs, Ultivue

Lorcan is an image analysis expert who previously spent 10 years in the pharmaceutical industry as a group leader (Organon, Schering-Plough, Merck & Co.). He led a group responsible for performing histology, immunohistochemistry / image analysis and he has considerable experience in developing translational biomarker strategies for projects across various therapeutic areas. He is a Prince 2® qualified project manager and has extensive experience in study management.

Author
Lorcan Sherry, PhD

Chief Science Officer, OracleBio

Categories: 5903 Development of specific multiplexed immunofluorescence immune assays to study mouse models of tumorigenesis
shape book
ebook

Development of specific multiplexed immunofluorescence immune assays to study mouse models of tumorigenesis

Register here for download

Relevant for

Collaboration, FixVUE, InSituPlex

Description Developing a multiplex immunofluorescence assay for the in depth characterization of activatedT cells in tumor tissue samples.

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 6083 Importance of Spatial Distribution Insight from Clinical Biopsies
shape Monitor
webinar
Jay Lee, MD, PhD

Director of R&D and Innovation, Ultivue

Importance of Spatial Distribution Insight from Clinical Biopsies

55 minutes

Relevant for

InSituPlex

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors. Advances in technology in the past few years have created unprecedented opportunities to better identify biomarkers of disease processes, especially by using multi-omics technologies and datasets to derive valid and useful signatures of disease. Despite these advances, today only a minority of patients respond to immunotherapies. Prediction of response to therapies such as checkpoint inhibitors that rely on activation of endogenous immune responses has been shown to be especially difficult due to complex and heterogeneous immune escape mechanisms in each patient. Increasing evidence suggests that measurement of robust biomarkers through spatial analysis of the tissue will be key to enable rational patient selection for an improved clinical trial process and design precise combination therapies. To date, much of what has been learned about the tumor microenvironment (TME) has come from the use of IHC, but information has been limited by labor-intensive protocols that yield single data points. IHC method sare therefore not sufficient for generating the comprehensive and interactive picture of the TME landscape. Newer technological approaches, such as multiplex immunofluorescence (mIF), provide greater resolution, better use of precious samples, and unparalleled insight into the spatial cellular arrangement within the tumor. The quantitative assessment of the accuracy and precision of such multiplex panels however is key for their widespread use in clinical samples.

Webinar Learning Objectives

The development and validation process of a high throughput, high-plex mIF assay to derive meaningful biological insights.

Demonstrate how advanced AI-driven image analysis can be applied to discover cell types, populations and morphological context.

Discuss how whole slide image analysis of the tumor microenvironment can provide insight into specific cancer types.

Meet the hosts

Angela Vasaturo is the Associate Director Scientific Affairs at Ultivue. Prior to joining Ultivue she was a Senior Researcher in Dr. Jerome Galon’s Laboratory of Integrative Cancer Immunology at the Cordeliers Research Centre. She has a wealth of expertise in multiplex IHC techniques, multispectral digital pathology, and tissue imaging.

Author
Angela Vasaturo, PhD

Associate Director Scientific Affairs, Ultivue

Categories: 6085 Improving Immuno-Oncology Research Using Spatial Phenomics
shape Monitor
webinar
Keith Wharton, MD, PhD, FCAP

Vice President, Medical Director, Ultivue

Improving Immuno-Oncology Research Using Spatial Phenomics

46 minutes

Relevant for

InSituPlex

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors. Advances in technology in the past few years have created unprecedented opportunities to better identify biomarkers of disease processes, especially by using multi-omics technologies and datasets to derive valid and useful signatures of disease. Despite these advances, today only a minority of patients respond to immunotherapies. Prediction of response to therapies such as checkpoint inhibitors that rely on activation of endogenous immune responses has been shown to be especially difficult due to complex and heterogeneous immune escape mechanisms in each patient. Increasing evidence suggests that measurement of robust biomarkers through spatial analysis of the tissue will be key to enable rational patient selection for an improved clinical trial process and design precise combination therapies. To date, much of what has been learned about the tumor microenvironment (TME) has come from the use of IHC, but information has been limited by labor-intensive protocols that yield single data points. IHC method sare therefore not sufficient for generating the comprehensive and interactive picture of the TME landscape. Newer technological approaches, such as multiplex immunofluorescence (mIF), provide greater resolution, better use of precious samples, and unparalleled insight into the spatial cellular arrangement within the tumor. The quantitative assessment of the accuracy and precision of such multiplex panels however is key for their widespread use in clinical samples.

Meet the hosts

Angela Vasaturo is the Associate Director Scientific Affairs at Ultivue. Prior to joining Ultivue she was a Senior Researcher in Dr. Jerome Galon’s Laboratory of Integrative Cancer Immunology at the Cordeliers Research Centre. She has a wealth of expertise in multiplex IHC techniques, multispectral digital pathology, and tissue imaging.

Author
Angela Vasaturo, PhD

Associate Director Scientific Affairs, Ultivue

Categories: 5869 Analysis of macrophages to the overall PD-L1 microenvironment using TMAs and InSituPlex
shape poster
poster

Presented at: ASCO 2022

Analysis of macrophages to the overall PD-L1 microenvironment using TMAs and InSituPlex

Register here for download

Relevant for

Collaboration, FixVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Authors

Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5816 Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
shape Monitor
webinar
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Length: 46 minutes

Relevant for

FixVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Webinar Learning Objectives

A better understanding of tumor heterogeneity, its immune environment and contextual relationship requires the spatial quantification of different immune and tumor cells along with the genetic background of the individual cancer.

The utilization of scRNA-seq and multiplexed Immunofluorescence techniques on NSCLC tumors to identify three main populations of intratumoral B and plasma cells.

An overview on the availability of digital tools in histopathology to allow interpreting the high-dimensional complexity of the spatial and immunological heterogeneity in tissue and integrating big (molecular) data to select the best and most effective treatment including combination and advanced therapies.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5848 Spatial multi-omics analysis targeting protein and RNA biomarkers on a single FFPE tissue section using an integrated staining and imaging workflow
shape poster
poster

Presented at: ASCO 2022

Spatial multi-omics analysis targeting protein and RNA biomarkers on a single FFPE tissue section using an integrated staining and imaging workflow

Register here for download

Relevant for

FixVUE, InSituPlex, RNA scope

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Authors

Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5847 Development of specific multiplexed immunofluorescence immune assays to study mouse models of tumorigenesis
shape poster
poster

Presented at: ASCO 2022

Development of specific multiplexed immunofluorescence immune assays to study mouse models of tumorigenesis

Register here for download

Relevant for

FixVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Authors

Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5828 High throughput tissue phenotyping and imaging of the tumor immune microenvironment using novel FlexVUE™multiplexed immunofluorescence assays
shape poster
poster

Presented at: ASCO 2022

High throughput tissue phenotyping and imaging of the tumor immune microenvironment using novel FlexVUE™multiplexed immunofluorescence assays

Register here for download

Relevant for

FlexVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Authors

Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5829 Improved Understanding of the Biology and Pathophysiology of the TME in PDAC Samples Revealed by Both InSituPlex and Imaging Mass Cytometry
shape poster
poster

Presented at: ASCO 2022

Improved Understanding of the Biology and Pathophysiology of the TME in PDAC Samples Revealed by Both InSituPlex and Imaging Mass Cytometry

Register here for download

Relevant for

Collaboration, FixVUE, Imaging mass cytometry, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Authors

Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5814 The power of data analytics in biomarker programs
shape Monitor
webinar
Moritz Widmaier, PhD

Senior Product Manager AI & Data Analytics

The power of data analytics in biomarker programs

Length: 10 minutes

Relevant for

FixVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5796 Introduction to Ultivue’s capabilities for immuno-oncology biomarker programs
shape Monitor
webinar
Moritz Widmaier, PhD; Branden Hopkinson, PhD

Senior Product Manager AI & Data Analytics

Introduction to Ultivue’s capabilities for immuno-oncology biomarker programs

Length: 20 minutes

Relevant for

FlexVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Meet the hosts

Moritz will drill his way through whatever intellectual challenge you’ll put in front of him. He previously perforated biochemistry, image analysis, data science, immuno-oncology biomarkers, product management/ownership. He’ll condense the best of our ideas into a coherent roadmap. His product backlog will guide us towards our vision one step at a time.

Author
Moritz Widmaier, PhD

Senior Product Manager AI & Data Analytics

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5782 FlexVUE case studies
shape Monitor
webinar
Kirsteen MacClean, PhD

Senior Director Scientific Brand Strategy

FlexVUE case studies

Length: 20 minutes

Relevant for

FlexVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5788 Gaining key phenotypic data from the tumor microenvironment using 8-plex immunofluorescence staining and image analysis
shape Monitor
webinar
Angela Vasaturo, PhD; Lorcan Sherry, PhD

Associate Director, Scientific Affairs Ultivue; Chief Science Officer, OracleBio

Gaining key phenotypic data from the tumor microenvironment using 8-plex immunofluorescence staining and image analysis

Length: 60 minutes

Relevant for

FixVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Lorcan is an image analysis expert who previously spent 10 years in the pharmaceutical industry as a group leader (Organon, Schering-Plough, Merck & Co.). He led a group responsible for performing histology, immunohistochemistry / image analysis and he has considerable experience in developing translational biomarker strategies for projects across various therapeutic areas. He is a Prince 2® qualified project manager and has extensive experience in study management.

Author
Lorcan Sherry, PhD

Chief Science Officer, OracleBio

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5786 FlexVUE for research
shape Monitor
webinar
Bonnie Philips, PhD

Senior Manager, FAS, North America

FlexVUE for research

Length: 20 minutes

Relevant for

FlexVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: